Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
20%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
4
31%
Ph phase_1
9
69%

Phase Distribution

9

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
9(69.2%)
Phase 2Efficacy & side effects
4(30.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Terminated(2)
Other(1)

Detailed Status

Completed10
Terminated1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
90.9%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (69.2%)
Phase 24 (30.8%)

Trials by Status

terminated18%
withdrawn18%
completed1077%
unknown18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

NCT02401503
unknownphase_2

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

NCT02471391
completedphase_1

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT01682616
terminatedphase_1

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
completedphase_2

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

NCT02677324
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT02401503Phase 2

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Completed
NCT02471391Phase 2

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Unknown
NCT01682616Phase 1

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Completed
NCT02203773Phase 1

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Terminated
NCT02677324Phase 2

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Completed
NCT01328626Phase 1

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Completed
NCT01594229Phase 1

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
NCT01794507Phase 1

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Completed
NCT01969695Phase 1

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Completed
NCT01994837Phase 2

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Completed
NCT01969669Phase 1

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Completed
NCT01686555Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Completed
NCT01969682Phase 1

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Withdrawn

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13